General Information of the Compound
| Compound ID |
CP0041905
|
||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Compound Name |
2-(2,6-dichloroanilino)-1,3-diazacyclopentene-(2)
Show/Hide
|
||||||||||||||||||
| Synonyms |
Adesipress
1H-Imidazol-2-amine, N-(2,6-dichlorophenyl)-4,5-dihydro-(9CI)
2,6-DICHLORO-N-IMIDAZOLIDIN-2-YLIDENEANILINE
2,6-Dichloro-N-2-imidazolidinylidenebenzenamine
2,6-dichloro-N-(2-imidazolidinylidene)aniline
2,6-dichloro-N-2-imidazolidinylidenebenzenamide
2,6-dichloro-N-imidazolidin-2-ylideneaniline
2-((2,6-Dichlorophenyl)imino)imidazolidine
2-(2,6-Dichloroanilino)-1,3-diazacyclopentene-(2);2-(2,6-Dichloroanilino)-2-imidazoline
2-(2,6-Dichloroanilino)-2-imidazoline
2-(2,6-Dichlorophenylamino)-2-imidazoline
2-(2,6-Dichlorophenylimino)imidazolidine
2-Imidazoline, 2-(2,6-dichloroanilino)-(7CI,8CI)
2-[(2,6-Dichlorophenyl)imino]imidazoline
2-[(2,6-dichlorophenyl)imino]-2-imidazoline
4205-90-7
734571A
Adesipress
CATAPRES-TTS-1
CATAPRES-TTS-2
CATAPRES-TTS-3
CLORPRES
Catapres
Catapres (TN)
Catapres- TTS
Catapres-TTS
Catapresan
Catapressan
Catarpres
Catarpres-TTS
Catarpres-TTS (TN)
Catarpresan
Chlornidinum
Clofenil
Clonidin
Clonidina
Clonidina [INN-Spanish]
Clonidine
Clonidine (JAN/USAN/INN)
Clonidine [USAN:BAN:INN]
Clonidinhydrochlorid
Clonidinum
Clonidinum [INN-Latin]
Clopheline
Dixarit
Duraclon
Duraclont
Gemiton
Hemiton
Isoglaucon
Klofelin
Klofenil
M 5041T
M-5041T
N-(2,6-Dichlorophenyl)-4,5-dihydro-1H-imidazol-2-amine
SKF 34427
ST 155BS
ST-155-BS
ST-155BS
Tenso-Timelets
clonidine
clonidine (amino form)
Show/Hide
|
||||||||||||||||||
| Structure |
|
||||||||||||||||||
| Formula |
C9H9Cl2N3
|
||||||||||||||||||
| Molecular Weight |
230.098
|
||||||||||||||||||
| Canonical SMILES |
Clc1cccc(Cl)c1N=C1NCCN1
Show/Hide
|
||||||||||||||||||
| InChI |
InChI=1S/C9H9Cl2N3/c10-6-2-1-3-7(11)8(6)14-9-12-4-5-13-9/h1-3H,4-5H2,(H2,12,13,14)
Show/Hide
|
||||||||||||||||||
| InChIKey |
GJSURZIOUXUGAL-UHFFFAOYSA-N
|
||||||||||||||||||
| CAS |
4205-90-7
|
||||||||||||||||||
| Physicochemical Property |
"RO5" indicates the cutoff set by lipinski's rule of five: (1) Molecular weight less than 500 Dalton; (2) xlogp less than 5; (3) No more than 5 hbonddonor (Hydrogen Bond Donor Count); (4) No more than 10 hbondacc (Hydrogen Bond Acceptor Count); (5) No more than 10 rotbonds (Rotatable Bond Count). Show/Hide
|
||||||||||||||||||
| Click to Show/Hide the External Link(s) of This Compound | |||||||||||||||||||
| PubChem ID | |||||||||||||||||||
| ChEMBL ID | |||||||||||||||||||
| DrugBank ID | |||||||||||||||||||
Map of Molecular Bioactivity Related to the Compound
|
Map of Molecular Bioactivity Related to the Compound Compound Cell Line Protein Bioactivity Value: <= 0.1 μM > 0.1 μM and <= 10 μM > 10 μM Imprecise Activity |
|
|---|
Table of Molecular Bioactivities Related to the Compound
Protein ID: PT00819, 5-hydroxytryptamine receptor 1A
Protein ID: PT02060, Alpha-1A adrenergic receptor
Protein ID: PT00644, Alpha-1B adrenergic receptor
Protein ID: PT01650, Alpha-2A adrenergic receptor
Cell-based Assay
Protein ID: PT02026, Alpha-2B adrenergic receptor
Protein ID: PT03109, Alpha-2B adrenergic receptor
Protein ID: PT01598, Alpha-2C adrenergic receptor
Protein ID: PT05367, Multidrug and toxin extrusion protein 1
Protein ID: PT02100, Nischarin
Protein ID: PT03795, Solute carrier family 22 member 1
Protein ID: PT06157, Solute carrier family 22 member 1
Clinical Information about the Compound